Dupilumab for Eczema: Spotlighting 4-Year Survival Rate Data; This long-term data on dupilumab investigated both survival rates and rationale for treatment discontinuation.

Media coverage

• Title	Dupilumab for Eczema: Spotlighting 4-Year Survival Rate Data; This long-term data on dupilumab investigated both survival rates and rationale for treatment discontinuation.
  Media name/outlet	Consultant Live
  Country/Territory	United States
  Date	19/11/23
  Persons	Bark-Lynn Lew

• Title	Dupilumab for Eczema: Spotlighting 4-Year Survival Rate Data
  Media name/outlet	HCP Live
  Country/Territory	United States
  Date	19/11/23
  Persons	Bark-Lynn Lew